Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disea... PR Newswire
Market data is delayed by at least 15 minutes.
    Latest Story
    Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
     PR Newswire

    -- On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025)

    -- Multiple Secondary Symptom Endpoints Met, Statistical Significance (P<0.025)

    -- On an Intent-to-Treat Analysis, Co-Primary Sign Endpoint and Secondary Sign Endpoints Not Met

    Full Story →

    Headline News
    Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
    7:30a ET February 15 '24 PR Newswire
    Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
    7:30a ET February 9 '24 PR Newswire
    Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
    7:30a ET February 5 '24 PR Newswire
    More News →
    Day  11.1%Week  9.74%Month  55.22%More Charting →
    Today, 11:29a ET Thursday March 28 '24. Markets Open.
    Last $1.78
    Day change   11.11%$0.18
    Open $1.61
    Gap at open $0.01
    Previous close $1.60
    Trading volume 188,269
    10 Day avg vol. 209,673
    Shares out. 16.1Mil
    Market cap. $28.7Mil
    Trading activity Above Avg.
    Previous data from yesterday, March 27 '24.

    Historical Price Performance
    3 month   55.33% 
    6 month   17.74% 
    1 year   34.88% 
    2 year   83.12% 

    Earnings
    Previous 12m -$2.48
    Next 12m Estimate -$2.13
    P/E ratio 0.7x
    Revenue 7Mil

    Market data provided by News provided by